Posts Tagged ‘statins

DISCUSSION
We are left with these facts about the use of statin drugs in adolescence:

Statins are highly effective for the short-term lowering of cholesterol and LDL-C levels.
They have a favorable side-effect profile and are well tolerated.

Certainly in adult medicine, persistent dyslipidemia may be countered with the addition of cholesterol-lowering drugs. Also, intrinsic to the decision to prescribe medications is a consideration of comorbidities such as diabetes, obesity, smoking, hypertension, along with knowledge of the patient’s pre-existing cardiovascular or peripheral vascular disease. Aside from the growing predisposition toward obesity, children rarely [...]

The first hurdle to clear is to identify who should be screened for hypercholesterolemia. Most practitioners agree on the American Heart Association’s recommendation of screening all children after two years of age who meet at least one of the following historical criteria:

any parent or grandparent with cardiovascular, cerebro-vascular, or peripheral vascular disease before age 55 [...]

Today, health care providers must ask themselves these questions:

Should we consider at-risk children for medical management with hypercholesterolemic drugs, particularly the class reputed to be the most effective, the HMG-CoA reductase inhibitors (statins)?
Should we recommend only lifestyle modification along with a low-fat or a low-carbohydrate diet and daily vigorous aerobic exercise?
Should we do neither—and possibly [...]

Kids and Statins

19, Feb 2010

INTRODUCTION
Our children are being relentlessly exposed to a cardiotoxic environment. High calorically dense, fat-enriched foods, and technologically aided sedentary lifestyles predispose future generations to cardiovascular insult. An idea once considered unimaginable a generation ago, more and more children are developing risk factors for coronary artery disease at an alarming rate.

Thiazolidinediones
Another area of investigation concerns the role of the thiazolidinediones in CVD prevention. RosigliĀ­tazone, a peroxisome proliferator-activated receptor (PPAR)-g agonist that is used in the treatment of type-2 diabetes, is also known to have anti-inflammatory effects. In 84 patients with stable, angio-graphically documented CAD and no diabetes who were randomized to rosiglitazone or placebo for [...]

Statin Therapy for Elevated CRP
In the last two decades, many randomized controlled trials of statin therapy have demonstrated that these agents reduce the risk of myocardial infarction (MI), stroke and other cardiovascular events in patients with known CVD and those at high risk. We also know that statins have a favorable effect on the atherogenic [...]

Pages: 1 2 Next

top